Journal: Cancers

Article Title: Fibroblasts Promote Resistance to KRAS Silencing in Colorectal Cancer Cells

doi: 10.3390/cancers16142595

Figure Lengend Snippet: List of anti-human antibodies used for flow cytometry.

Article Snippet: CD49f , APC , GoH3 , 130-100-147 , Miltenyi Biotec.

Techniques: Cytometry

Journal: Stem Cell Reports

Article Title: Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

doi: 10.1016/j.stemcr.2017.03.026

Figure Lengend Snippet: The CD49f+ Population Is Enriched after Acquisition of Resistance to Docetaxel (A) Frequency of indicated markers within the H2Kd– population in IDB-01 and IDB-02, sensitive and resistant tumors analyzed by flow cytometry at passage 3, at least 5 days after the last docetaxel treatment. Total number of tumors analyzed (n) mean values, SDs and t test p values are shown. ∗ 0.01 < p < 0.05; ∗∗ 0.001 < p < 0.01. (B) Box and whiskers (min to max) graph showing expression levels of CD49f and EpCAM mRNA relative to PPiA in additional sensitive and resistant tumors measured by qRT-PCR. Determinations were done in triplicate and means are used. t test p values for significant differences are shown. ∗∗ 0.001 < p < 0.01. (C) Box and whiskers (min to max) graph showing association of CD49f and EpCAM with chemotherapy response in 74 patients with basal-like breast cancer EORTC ( Bonnefoi et al., 2011 ). Response was measured as pathological complete response (pCR) or residual disease (RD). t test p values are shown. (D) Kaplan-Meier analysis of overall survival of ER-tumors all treated with chemotherapy using CD49f and EpCAM mRNA expression in the clinical dataset (GSE16446) from the TOP TRIAL ( Desmedt et al., 2011 ). See also and .

Article Snippet: Then they were labeled with antibodies against CD24-PE (555428), CD44-APC (559942), EpCAM-FITC (347197), CD10-PECy5 (555376), and CD49f-A647 (562473) (all from BD Pharmingen), CD133/1-PE (130-098-826 from Miltenyi Biotec), and CD49f-APC (FAB13501A from R&D Systems).

Techniques: Flow Cytometry, Expressing, Quantitative RT-PCR

Journal: Stem Cell Reports

Article Title: Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

doi: 10.1016/j.stemcr.2017.03.026

Figure Lengend Snippet: CD49f Expression Increases in Residual Disease of Most TNBC PDX Tumors after Treatment with Docetaxel, but Not on Resistant Tumors (A) Scheme of short-term docetaxel treatment and CD49f mRNA expression levels in sensitive tumors from IDB-01S and IDB-02S after short-term treatment with docetaxel (DTX) and in untreated controls (CT). Each dot represents one tumor. ∗ 0.01 < p < 0.05; ∗∗ 0.001 < p < 0.01. (B) Frequency of CD49f+ cells within H2Kd– in IDB-01S tumors after two to three doses of docetaxel and in IDB-01R tumors that have been treated with docetaxel (at least 5 days after last treatment) or growing in the absence of docetaxel for two and five passages. ∗ 0.01 < p < 0.05; ∗∗ 0.001 < p < 0.01. (C and D) Docetaxel-sensitive tumors (C) and docetaxel-resistant tumors (D). Top panels: tumor size of the indicated PDX tumors treated with docetaxel (20 mg/kg, arrows) and corresponding controls relative to the size at the first day of treatment. n = total number of tumors. ∗∗∗∗ p < 0.0001. Bottom panels: CD49f mRNA expression levels in PDX tumors after short-term treatment with docetaxel and in untreated controls. Each dot represents one tumor. ∗ 0.01 < p < 0.05; ∗∗ 0.001 < p < 0.01; ∗∗∗ 0.001 < p < 0.0001. (A–D) Mean values, SEM, and t test p values are shown in all cases. See also Figure S5 .

Article Snippet: Then they were labeled with antibodies against CD24-PE (555428), CD44-APC (559942), EpCAM-FITC (347197), CD10-PECy5 (555376), and CD49f-A647 (562473) (all from BD Pharmingen), CD133/1-PE (130-098-826 from Miltenyi Biotec), and CD49f-APC (FAB13501A from R&D Systems).

Techniques: Expressing

Journal: Stem Cell Reports

Article Title: Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

doi: 10.1016/j.stemcr.2017.03.026

Figure Lengend Snippet: CD49f Expression Increases in Surviving TNBC Cells after Treatment with Docetaxel (A and B) Top panels: percentage of surviving cells treated with docetaxel for 72 h (A) or 8 h (B). Bottom panels: CD49f mRNA expression levels in the indicated TNBC cell lines treated with docetaxel relative to untreated controls. ∗ 0.01 < p < 0.05; ∗∗ 0.001 < p < 0.01; ∗∗∗ 0.001 < p < 0.0001. (C and D) CD49f mRNA expression levels (C) and CD49f protein expression measured by flow cytometry (D) in cells stably infected with two independent shCD49f knockdown constructs and control vector (pGIPZ). (E) Percentage of surviving shCD49f-infected and control pGIPZ-infected cells treated with indicated doses of docetaxel for 72 hr. RT-PCR Determinations were done in triplicate and means are used in the calculations. Mean values of three independent experiments, SEM, and t test p values for the higher concentrations are shown. See also Figure S5 .

Article Snippet: Then they were labeled with antibodies against CD24-PE (555428), CD44-APC (559942), EpCAM-FITC (347197), CD10-PECy5 (555376), and CD49f-A647 (562473) (all from BD Pharmingen), CD133/1-PE (130-098-826 from Miltenyi Biotec), and CD49f-APC (FAB13501A from R&D Systems).

Techniques: Expressing, Flow Cytometry, Stable Transfection, Infection, Knockdown, Construct, Control, Plasmid Preparation, Reverse Transcription Polymerase Chain Reaction

Journal: Stem Cell Reports

Article Title: Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

doi: 10.1016/j.stemcr.2017.03.026

Figure Lengend Snippet: CD49f+ Population Is Enriched in Tumor-Initiating Cells with Increased Resistance to Docetaxel (A) Scheme of functional experiments. (B and E) Table showing limiting dilution assay of CD49f+/hi and CD49f− tumor cells from IDB-01 (B) and IDB-02 (E) cells. Tumor-initiating cell frequency (with confidence intervals) for each group was calculated by ELDA; chi-square values and associated probabilities are shown. (C and G) Frequency of CD49f+ cells in tumors derived from indicated cells. Mean values, SEM, and significant t test p values are shown. ∗∗ 0.001 < p < 0.01; ∗∗∗ 0.001 < p < 0.0001. (D and H) Kinetics of tumor growth during docetaxel treatment in tumors derived from indicated cells. Mean values, SEM, and t test p values are shown. ∗∗ 0.001 < p < 0.01; ∗∗∗∗ p <0.0001. (F) Latency of tumors derived from the injection of the indicated number of IDB-02S-CD49f+/hi and 02S-CD49f− tumor cells. Mean values, SEM and significant t test p values are shown. ∗∗ 0.001 < p < 0.01. (I) Unsupervised analysis of all CD49f sorted samples from IDB-01S and -01R tumors using 105 breast cancer-related genes. The type of sample and tumor are shown below the array tree. Each square represents the relative transcript abundance. See also Figure S6 .

Article Snippet: Then they were labeled with antibodies against CD24-PE (555428), CD44-APC (559942), EpCAM-FITC (347197), CD10-PECy5 (555376), and CD49f-A647 (562473) (all from BD Pharmingen), CD133/1-PE (130-098-826 from Miltenyi Biotec), and CD49f-APC (FAB13501A from R&D Systems).

Techniques: Functional Assay, Limiting Dilution Assay, Derivative Assay, Injection